The Bladder cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Bladder cancer Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Bladder cancer Market.

Some of the key takeaways from the Bladder cancer Pipeline Report:

• Companies across the globe are diligently working toward developing novel Bladder cancer treatment therapies with a considerable amount of success over the years. 
• Bladder cancer companies working in the treatment market are Ractigen Therapeutics, XNK Therapeutics, Vaxiion Therapeutics, Vyriad, Inc., Istari Oncology Inc., Theralase Technologies Inc., Taiho Oncology, Inc, Lepu Biopharma CO.,Ltd., Janssen Research & Development, LLC, Asieris Pharmaceuticals, ImmunityBio, CG Oncology, UroGen, G1 Therapeutics, BeiGene, and others, are developing therapies for the Bladder cancer treatment 

• Emerging Bladder cancer therapies in the different phases of clinical trials are- RAG-01, XNK03, VAX014, MV-NIS, Lerapolturev, TLD-1433, Futibatinib, HX-008, TAR-200, APL-1202, N-803, CG0070, UGN-102, Trilaciclib, Tislelizumab, and others are expected to have a significant impact on the Bladder cancer market in the coming years.   
• In July 2022, The United States Food and Drug Administration (FDA) agreed to review ImmunityBio’s Biologics License Application (BLA) for N-803 in patients with or without Ta or T1 illness who have non-muscle-invasive bladder cancer (NMIBC) carcinoma in situ (CIS).
• In July 2022, Nanostics Inc., launched a prospective clinical study designed to validate a novel and minimally invasive bladder cancer diagnostic test, ClarityDX Bladder, using its ClarityDX diagnostic platform. In partnership with the University of Alberta’s Alberta Prostate Cancer Research Initiative (APCaRI) and DynaLIFE Medical Labs.

Bladder cancer Overview

Bladder cancer is a type of cancer that begins in the cells of the bladder, the organ responsible for storing urine. It is one of the more common cancers, and the majority of bladder cancers originate in the inner lining of the bladder, known as the urothelium. However, cancers can also develop in other types of cells in the bladder.

Get a Free Sample PDF Report to know more about Bladder cancer Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/bladder-cancer-pipeline-insight

Emerging Bladder cancer Drugs Under Different Phases of Clinical Development Include:

• RAG-01: Ractigen Therapeutics
• XNK03: XNK Therapeutics
• VAX014: Vaxiion Therapeutics
• MV-NIS: Vyriad, Inc.
• Lerapolturev: Istari Oncology Inc.
• TLD-1433: Theralase Technologies Inc.
• Futibatinib: Taiho Oncology, Inc
• HX-008: Lepu Biopharma CO.,Ltd.
• TAR-200: Janssen Research & Development, LLC
• APL-1202: Asieris Pharmaceuticals
• N-803: ImmunityBio
• CG0070: CG Oncology
• UGN-102: UroGen
• Trilaciclib: G1 Therapeutics
• Tislelizumab: BeiGene

Bladder cancer Route of Administration

Bladder cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Bladder cancer Molecule Type

Bladder cancer Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy 

Bladder cancer Pipeline Therapeutics Assessment

• Bladder cancer Assessment by Product Type
• Bladder cancer By Stage and Product Type
• Bladder cancer Assessment by Route of Administration
• Bladder cancer By Stage and Route of Administration
• Bladder cancer Assessment by Molecule Type
• Bladder cancer by Stage and Molecule Type

DelveInsight’s Bladder cancer Report covers around 100+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Bladder cancer product details are provided in the report. Download the Bladder cancer pipeline report to learn more about the emerging Bladder cancer therapies

Some of the key companies in the Bladder cancer Therapeutics Market include:

Key companies developing therapies for Bladder cancer are – CG Oncology, FKD Therapies, Bristol-Myers Squibb, LintonPharm Co., Ltd., ImmunityBio, Inc., Hamlet Pharma AB, Asieris Pharmaceuticals, Pfizer, Taizhou Hanzhong biomedical co. LTD, Protara Therapeutics, CicloMed LLC, enGene, Inc., Emtora Biosciences, Theralase Inc.,  Vaxiion Therapeutics, Janssen Research & Development, LLC, Astellas Pharma, RemeGen Co., Ltd., UroGen Pharma Ltd., Flame Biosciences, Aura Biosciences, BeiGene, Incyte Corporation, QED Therapeutics, G1 Therapeutics, AN0025, Kyowa Kirin, Inc., Infinity Pharmaceuticals, Shanghai Hengrui Pharmaceutical Co., Ltd., HiberCell, and others.

Bladder cancer Pipeline Analysis:

The Bladder cancer pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Bladder cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Bladder cancer Treatment.
• Bladder cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Bladder cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Bladder cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Bladder cancer drugs and therapies

Bladder cancer Pipeline Market Drivers

• Increase in the number of patients suffering from non-muscle invasive bladder cancer, development of novel therapies and favorable government policies are some of the important factors that are fueling the Bladder cancer Market.

Bladder cancer Pipeline Market Barriers

• However, identifying the patient population with specific mutations for targeted therapy regimens, lack of awareness about the advanced cancer therapies and other factors are creating obstacles in the Bladder cancer Market growth.

Scope of Bladder cancer Pipeline Drug Insight    

• Coverage: Global
• Key Bladder cancer Companies: Ractigen Therapeutics, XNK Therapeutics, Vaxiion Therapeutics, Vyriad, Inc., Istari Oncology Inc., Theralase Technologies Inc., Taiho Oncology, Inc, Lepu Biopharma CO.,Ltd., Janssen Research & Development, LLC, Asieris Pharmaceuticals, ImmunityBio, CG Oncology, UroGen, G1 Therapeutics, BeiGene, and others
• Key Bladder cancer Therapies: RAG-01, XNK03, VAX014, MV-NIS, Lerapolturev, TLD-1433, Futibatinib, HX-008, TAR-200, APL-1202, N-803, CG0070, UGN-102, Trilaciclib, Tislelizumab, and others
• Bladder cancer Therapeutic Assessment: Bladder cancer current marketed and Bladder cancer emerging therapies
• Bladder cancer Market Dynamics: Bladder cancer market drivers and Bladder cancer market barriers 

Request for Sample PDF Report for Bladder cancer Pipeline Assessment and clinical trials

Table of Contents

1. Bladder cancer Report Introduction

2. Bladder cancer Executive Summary

3. Bladder cancer Overview

4. Bladder cancer- Analytical Perspective In-depth Commercial Assessment

5. Bladder cancer Pipeline Therapeutics

6. Bladder cancer Late Stage Products (Phase II/III)

7. Bladder cancer Mid Stage Products (Phase II)

8. Bladder cancer Early Stage Products (Phase I)

9. Bladder cancer Preclinical Stage Products

10. Bladder cancer Therapeutics Assessment

11. Bladder cancer Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Bladder cancer Key Companies

14. Bladder cancer Key Products

15. Bladder cancer Unmet Needs

16 . Bladder cancer Market Drivers and Barriers

17. Bladder cancer Future Perspectives and Conclusion

18. Bladder cancer Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services